rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Maria-Luisa Maccecchini

Director

Company insider

Files Form 4 as: Director, Lantern Pharma; President & CEO, Annovis Bio; Director, Competitive Technologies.

Every Form 4 they filed

In numbers

Trades disclosed
45
Buys
4
Sells
0
Bought
$715K
Sold
$0
Companies
3
Companies where not an officer
2
First trade
3 Jan 2006
Last trade
9 Jan 2026
Last filed
13 Jan 2026

Companies traded

Where they are an officer
ANVS Annovis BioDirector, Officer, 10% owner · Biotechnology · last 28 Oct 20253 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
LTRN Lantern PharmaDirector · Biotechnology · last 9 Jan 20260 buys · 0 sells
Competitive TechnologiesDirector · last 4 Jan 20071 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
9 Jan 2026filed 13 Jan 2026LTRN Lantern Pharmaoption or derivative · BiotechnologySEC FORM 4 Code A—25,000 at $0.00filing
9 Jan 2026filed 13 Jan 2026LTRN Lantern Pharmaoption or derivative · BiotechnologySEC FORM 4 Code A—21,152 at $0.00filing
9 Jan 2026filed 13 Jan 2026LTRN Lantern Pharmaoption or derivative · BiotechnologySEC FORM 4 Code A—25,000 at $0.00filing
9 Jan 2026filed 13 Jan 2026LTRN Lantern Pharmaoption or derivative · BiotechnologySEC FORM 4 Code A—21,152 at $0.00filing
28 Oct 2025filed 12 Nov 2025ANVS Annovis BioBiotechnologySEC FORM 4 Bought$200K97,561 at $2.05filing
4 Jun 2025filed 5 Jun 2025ANVS Annovis BioBiotechnologySEC FORM 4 Code A$155K46,000 at $3.37filing
15 Jul 2024filed 17 Jul 2024LTRN Lantern Pharmaoption or derivative · BiotechnologySEC FORM 4 Code A—5,000 at $0.00filing
31 Mar 2024filed 3 Jul 2024ANVS Annovis BioBiotechnologySEC FORM 4 Code G—10,000 at $0.00filing
31 Mar 2024filed 3 Jul 2024ANVS Annovis BioBiotechnologySEC FORM 4 Code G—10,000 at $0.00filing
28 Mar 2024filed 3 Jul 2024ANVS Annovis BioBiotechnologySEC FORM 4 Code G—10,000 at $0.00filing
20 Nov 2023filed 22 Nov 2023ANVS Annovis BioBiotechnologySEC FORM 4 Code A$250K40,970 at $6.10filing
20 Nov 2023filed 21 Nov 2023ANVS Annovis BioBiotechnologySEC FORM 4 Code A$250K41,186 at $6.07filing
17 Nov 2023filed 3 Jul 2024ANVS Annovis Biooption or derivative · BiotechnologySEC FORM 4 Code A—252,000 at $0.00filing
17 Nov 2023filed 3 Jul 2024ANVS Annovis Biooption or derivative · BiotechnologySEC FORM 4 Code A—108,800 at $0.00filing
24 Apr 2023filed 26 Apr 2023ANVS Annovis BioBiotechnologySEC FORM 4 Code G—3,000 at $0.00filing
7 Apr 2023filed 11 Apr 2023ANVS Annovis BioBiotechnologySEC FORM 4 Code A$252K20,000 at $12.61filing
6 Feb 2023filed 8 Feb 2023ANVS Annovis Biooption or derivative · BiotechnologySEC FORM 4 Code M—52,755 at $0.00filing
6 Feb 2023filed 8 Feb 2023ANVS Annovis BioBiotechnologySEC FORM 4 Code M$7,38652,755 at $0.14filing
18 Jan 2023filed 20 Jan 2023ANVS Annovis Biooption or derivative · BiotechnologySEC FORM 4 Code A—21,312 at $0.00filing
20 Oct 2022filed 24 Oct 2022LTRN Lantern Pharmaoption or derivative · BiotechnologySEC FORM 4 Code A—3,200 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care3
Not placed1

Buys in green, sells in red, by the company’s sector.

Related people

Michael B. HoffmanChairman and CEO · Director at Annovis Bio, filing Form 4 there in the last year